vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1285Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWФАКТОРЫ РИСКА РАННЕГО РАЗВИТИЯ КАРДИОВАСКУЛЯРНОЙПАТОЛОГИИ У ДЕТЕЙ, СТРАДАЮЩИХ ЮВЕНИЛЬНЫМ РЕВМАТОИДНЫМ АРТРИТОМRISK FACTORS OF EARLY CARDIOVASCULAR PATHOLOGY OF CHILDREN SUFFERING FROM JUVENILE RHEUMATIC ARTHRITISГудковаЕ.Ю.GudkovaE.Yu.АлексееваЕ.И.AlexeevaE.I.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowRussian Federation20072110201565Вопросы современной педиатрии7480Copyright © Гудкова Е., Алексеева Е., 20072007Гудкова Е., Алексеева Е.Gudkova E., Alexeeva E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1285ReferencesКлинические рекомендации. Ревматология. Под ред. Е.Л. Насонова М.: ГЭОТАР-Медиа. 2005.Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова М.: ГЭОТАР-Медиа. 2005.Алексеева Е.И., Жолобова Е.С., Чистякова Е.Г, Бзарова Т.М. Ювенильный ревматоидный артрит. Учебно-методическое пособие. М. 2004.Алексеева Е.И., Жолобова Е.С., Чистякова Е.Г, Бзарова Т.М. Ювенильный ревматоидный артрит. Учебно-методическое пособие. М. 2004.Goodson N. Coronary artery disease and rheumatoid arthritis. Curr. Opin. Rheumatol. 2002; 14: 115–120.Goodson N. Coronary artery disease and rheumatoid arthritis. Curr. Opin. Rheumatol. 2002; 14: 115–120.Goodson N., Marks J., Lunt M. et al. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Arthritis Rheum. 2005.Goodson N., Marks J., Lunt M. et al. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Arthritis Rheum. 2005.Pincus T., Sokka T., Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001; 44: 1234-1236.Pincus T., Sokka T., Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001; 44: 1234-1236.Maradit–Kremers H., Crowson C.S., Nicola P.J. et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. A population based controlled study. Arthritis Rheum. 2005; 52: 722–732.Maradit–Kremers H., Crowson C.S., Nicola P.J. et al. Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. A population based controlled study. Arthritis Rheum. 2005; 52: 722–732.Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in Early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002; 46: 2010–2019.Goodson N.J., Wiles N.J., Lunt M. et al. Mortality in Early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002; 46: 2010–2019.Kitas G.D., Blank M.J., Bacon P.A. Cardiac involvement in rheumatoid disease. Clin. Med. JRCPL. 2001; 1: 18–21.Kitas G.D., Blank M.J., Bacon P.A. Cardiac involvement in rheumatoid disease. Clin. Med. JRCPL. 2001; 1: 18–21.Van Dorum S., McColl G., Wicks I.P. Accelerated atherosclerosis. An exraarticular feature of rheumatoid arthritis. Arthritis Rheum. 2002; 46: 862–875.Van Dorum S., McColl G., Wicks I.P. Accelerated atherosclerosis. An exraarticular feature of rheumatoid arthritis. Arthritis Rheum. 2002; 46: 862–875.Kitas G.D., Erb N. Tackling ischemic heart disease in rheumatoid arthritis. Rheumatology. 2003; 42: 607–613.Kitas G.D., Erb N. Tackling ischemic heart disease in rheumatoid arthritis. Rheumatology. 2003; 42: 607–613.Sattar N., McCrey D.W., Capell H., McInnes I.B. Explaining how “high-grade” systemic inflammation accelerated vascular risk in rheumatoid arthritis. Circulation. 2003; 108: 2957–2963.Sattar N., McCrey D.W., Capell H., McInnes I.B. Explaining how “high-grade” systemic inflammation accelerated vascular risk in rheumatoid arthritis. Circulation. 2003; 108: 2957–2963.Manzi S., Wasco M.C. Inflammation mediated rheumatic disease and atherosclerosis. Ann. Rheum. Dis. 2000; 59: 321–325.Manzi S., Wasco M.C. Inflammation mediated rheumatic disease and atherosclerosis. Ann. Rheum. Dis. 2000; 59: 321–325.Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003; 7: 6-10.Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестник РАМН. 2003; 7: 6-10.Chung C.P., Avalos I., Raggi P. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (8): 1228–1233.Chung C.P., Avalos I., Raggi P. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol. 2007; 26 (8): 1228–1233.Насонов Е.Л. Иммунологические маркеры атеросклероза. Терапевтический архив. 2002; 5: 80–85.Насонов Е.Л. Иммунологические маркеры атеросклероза. Терапевтический архив. 2002; 5: 80–85.Szmitko P.E., Wang C.H., Weisel R.D. et al. New markers of inflammation and endothelial cell activation. Part I. Circulation. 2003; 108: 1917–1923.Szmitko P.E., Wang C.H., Weisel R.D. et al. New markers of inflammation and endothelial cell activation. Part I. Circulation. 2003; 108: 1917–1923.Szmitko P.E., Wang C.H., Weisel R.D. et al. New markers of inflammation and endothelial cell activation, part II. Circulation. 2003; 108: 2041–2048.Szmitko P.E., Wang C.H., Weisel R.D. et al. New markers of inflammation and endothelial cell activation, part II. Circulation. 2003; 108: 2041–2048.Насонов Е.Л. Иммунологические маркеры атеросклероза. В кн.: Антифосфолипидный синдром. М.: Литера. 2004. С. 278–298.Насонов Е.Л. Иммунологические маркеры атеросклероза. В кн.: Антифосфолипидный синдром. М.: Литера. 2004. С. 278–298.Malle E., De Beer F.C. Human serum amyloid A protein: a promising acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 1996; 26: 427–435.Malle E., De Beer F.C. Human serum amyloid A protein: a promising acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 1996; 26: 427–435.Morrow D. L., Rifai N., Antman E.M. et al. Serum amyloid A predictive early mortality in acute coronary syndrome: a TIMI 11A sub study. Am. Coll. Cardiol. 2000; 35: 358–362.Morrow D. L., Rifai N., Antman E.M. et al. Serum amyloid A predictive early mortality in acute coronary syndrome: a TIMI 11A sub study. Am. Coll. Cardiol. 2000; 35: 358–362.Biasucci L., Liuzzo G., Grillo R. et al. Elevated levels of C-reactive protein at discharge in patient with unstable angina predict recurrent instability. Circulation. 1999; 99: 855–860.Biasucci L., Liuzzo G., Grillo R. et al. Elevated levels of C-reactive protein at discharge in patient with unstable angina predict recurrent instability. Circulation. 1999; 99: 855–860.Насонова В.А., Бунчук Н.В. Ревматические болезни. Руководство по внутренним болезням. М.: Медицина. 1997.Насонова В.А., Бунчук Н.В. Ревматические болезни. Руководство по внутренним болезням. М.: Медицина. 1997.De Bendetti F., Massa M., Robbioni P. et al Correlation of serum interleukin-6 levels with joint involvement and trombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.De Bendetti F., Massa M., Robbioni P. et al Correlation of serum interleukin-6 levels with joint involvement and trombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.Rooney M., David J., Symmons J. et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheumatol. 1995; 34: 454–460.Rooney M., David J., Symmons J. et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheumatol. 1995; 34: 454–460.De Bendetti F., Massa M., Pignatti P. et al. Serum soluble interleukin-6 receptor and interleukin-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. 1994; 93: 2114–2119.De Bendetti F., Massa M., Pignatti P. et al. Serum soluble interleukin-6 receptor and interleukin-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. 1994; 93: 2114–2119.Peake N.J., Khawaja K., Myeis A. Interleukin–6 signalling in juvenile rheumatoid arthritis is limited by proteolytically cleaved soluble interleukin–6 receptor. Rheumatology. 2006; 45 (12): 1485–1489.Peake N.J., Khawaja K., Myeis A. Interleukin–6 signalling in juvenile rheumatoid arthritis is limited by proteolytically cleaved soluble interleukin–6 receptor. Rheumatology. 2006; 45 (12): 1485–1489.Keul R., Heinrich P.C., Muller-Newen G. et al. A possible role of soluble interleukin–6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine. 1998; 10: 729.Keul R., Heinrich P.C., Muller-Newen G. et al. A possible role of soluble interleukin–6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine. 1998; 10: 729.Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of feature myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767–1772.Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of feature myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767–1772.Harris T.B., Ferrucci I., Traxy R.P. et al. Associations of elevated interleukin-6 and C-protein levels with mortality in the elderly. Am. J. Med. 1999; 106: 506–512.Harris T.B., Ferrucci I., Traxy R.P. et al. Associations of elevated interleukin-6 and C-protein levels with mortality in the elderly. Am. J. Med. 1999; 106: 506–512.Lee W.Y., Allison M.A., Kim D.J. Association of interleukin–6 and C–reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am. J. Cardiol. 2007; 99 (1): 99-102.Lee W.Y., Allison M.A., Kim D.J. Association of interleukin–6 and C–reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am. J. Cardiol. 2007; 99 (1): 99-102.Rooney M., Varsani H., Martin K. et al. Tumour necrosis factor alpha and its soluble receptorsin juvenile chronic arthritis. Rheumatology (Oxford). 2000; 39: 432–438.Rooney M., Varsani H., Martin K. et al. Tumour necrosis factor alpha and its soluble receptorsin juvenile chronic arthritis. Rheumatology (Oxford). 2000; 39: 432–438.Gattorno M., Picco P., Buoncompagni A. et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann. Rheum. Dis. 1996; 55: 243.Gattorno M., Picco P., Buoncompagni A. et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann. Rheum. Dis. 1996; 55: 243.Abramson S.B., Amin A. Blocking the effects of ИЛ 1 in rheumatoil arthritis protects bone and cartilage. Rheumatology (Oxford). 2002; 41 (9): 972–980.Abramson S.B., Amin A. Blocking the effects of ИЛ 1 in rheumatoil arthritis protects bone and cartilage. Rheumatology (Oxford). 2002; 41 (9): 972–980.Cassidy P., Lindsley L. Textbook of Pediatric Rheumatology. 5th edition. USA. 2006.Cassidy P., Lindsley L. Textbook of Pediatric Rheumatology. 5th edition. USA. 2006.Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patient with rheumatoid arthritis. Adv. Ther. 2006; 23 (2): 208–217.Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patient with rheumatoid arthritis. Adv. Ther. 2006; 23 (2): 208–217.Weiss G., Willei J., Kiechl S. et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. 1994; 106: 263–271.Weiss G., Willei J., Kiechl S. et al. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. 1994; 106: 263–271.Erren M., Reinecke H., Junker R. et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral artheries. Artherioscler. Thromb. Vasc. Biol. 1999; 19: 338–339.Erren M., Reinecke H., Junker R. et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral artheries. Artherioscler. Thromb. Vasc. Biol. 1999; 19: 338–339.Garica-Moll N., Coccolo F., Cole D et al. Serum neopterin and complexes stenosis morphology in patients with unstable angina. Artherioscler. Thromb. Vasc. Biol. 2000; 35: 956–962.Garica-Moll N., Coccolo F., Cole D et al. Serum neopterin and complexes stenosis morphology in patients with unstable angina. Artherioscler. Thromb. Vasc. Biol. 2000; 35: 956–962.Gurfinkel E.P., Scirica B.M., Borovich G. et al Serum neopterin levels and the angiographic extent of coronary arterial narrowing in instable angina pectoris and non-Q wave acute myocardial infarction. Am. J. Cardiol. 1999; 83: 515–518.Gurfinkel E.P., Scirica B.M., Borovich G. et al Serum neopterin levels and the angiographic extent of coronary arterial narrowing in instable angina pectoris and non-Q wave acute myocardial infarction. Am. J. Cardiol. 1999; 83: 515–518.Насонов Е.Л., Самсонов М.Ю., Tilz G., Fuhs D. Неоптерин — новый иммунологический маркер аутоиммунных ревматических заболеваний. Клиническая медицина. 2000; 8: 43–46.Насонов Е.Л., Самсонов М.Ю., Tilz G., Fuhs D. Неоптерин — новый иммунологический маркер аутоиммунных ревматических заболеваний. Клиническая медицина. 2000; 8: 43–46.Moncada S., Palmer R.M.J., Higgs E.A. Biosynthesis of nitric oxide from L–arginine: a pathway for the regulation of cell function and communication. Biochem. Pharmacol. 1989; 38: 1709–1715.Moncada S., Palmer R.M.J., Higgs E.A. Biosynthesis of nitric oxide from L–arginine: a pathway for the regulation of cell function and communication. Biochem. Pharmacol. 1989; 38: 1709–1715.Palmer R.M.J., Mineau F., Ranger P et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium dependent relaxation. Biochem. Biophys. Res. Comm. 1988; 153: 1251–1256.Palmer R.M.J., Mineau F., Ranger P et al. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium dependent relaxation. Biochem. Biophys. Res. Comm. 1988; 153: 1251–1256.Горрен А.К.Ф., Майер Б. Универсальная и комплексная энзимология синтазы азота // Обзор. Биохимия. 1998; 7: 870–880.Горрен А.К.Ф., Майер Б. Универсальная и комплексная энзимология синтазы азота // Обзор. Биохимия. 1998; 7: 870–880.Das P., Schurman D.J., Lane S.R. Nitric oxide and G proteins mediate the response of bovine articular chondrocytes to fluid-induced shear. J. Orthop. Res. 1997; 15: 87–93.Das P., Schurman D.J., Lane S.R. Nitric oxide and G proteins mediate the response of bovine articular chondrocytes to fluid-induced shear. J. Orthop. Res. 1997; 15: 87–93.Lotz M., Bober L., Narula S. et al ИЛ 17 promotes cartilage degradation (abstract). Arth. Rheum. 1996; 39: 120.Lotz M., Bober L., Narula S. et al ИЛ 17 promotes cartilage degradation (abstract). Arth. Rheum. 1996; 39: 120.Rediske J., Koehne C., Zhang B. et al. Inducible production of nitric oxide by articular cell types. Osteoarthrit. Cart. 1994; 2: 199–206.Rediske J., Koehne C., Zhang B. et al. Inducible production of nitric oxide by articular cell types. Osteoarthrit. Cart. 1994; 2: 199–206.Charles I.S., Palmer R.M., Hickery M.S. et al. Cloning, characterization and expression of cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc. Nat. Acad. Sci. 1993; 90: 11419–11423.Charles I.S., Palmer R.M., Hickery M.S. et al. Cloning, characterization and expression of cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc. Nat. Acad. Sci. 1993; 90: 11419–11423.Maier R., Bilbe G., Rediske J. et al. Inducible nitric oxide syntase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochem. Biophys. Acta. 1994; 1208: 145–150.Maier R., Bilbe G., Rediske J. et al. Inducible nitric oxide syntase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochem. Biophys. Acta. 1994; 1208: 145–150.Mendes A.F., Carvalho A.P., Caramona M.M. et al. Role of nitric oxide in activation of NF-kappa B, AP-1 and NOS II expression in articular chondrocytes. Inflamm. Res. 2002; 51 (7): 369–375.Mendes A.F., Carvalho A.P., Caramona M.M. et al. Role of nitric oxide in activation of NF-kappa B, AP-1 and NOS II expression in articular chondrocytes. Inflamm. Res. 2002; 51 (7): 369–375.McCartney-Francis N., Allen J.B., Mizel D.E. et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 1993; 178: 149–154.McCartney-Francis N., Allen J.B., Mizel D.E. et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J. Exp. Med. 1993; 178: 149–154.Stefanovic-Racic M., Meyers K., Meschter C. et al. N–monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum. 1994; 37: 1062–1069.Stefanovic-Racic M., Meyers K., Meschter C. et al. N–monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum. 1994; 37: 1062–1069.Ialenti A., Moncada S., Di Rosa M. et al. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 1993; 110: 701–706.Ialenti A., Moncada S., Di Rosa M. et al. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 1993; 110: 701–706.van`t Hof R.J., Hocking L., Wright P.K. et al. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology. 2000; 39: 1004–1008.van`t Hof R.J., Hocking L., Wright P.K. et al. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology. 2000; 39: 1004–1008.Veihelmann A., Hofbauer A., Krombach F. et al. Differencial function of nifric oxide in murine antigen-induced arthritis. Rheumatology. 2002; 41: 509–517.Veihelmann A., Hofbauer A., Krombach F. et al. Differencial function of nifric oxide in murine antigen-induced arthritis. Rheumatology. 2002; 41: 509–517.Ling S., Lai A., Borschukova O. et al. Activation of nitric oxide signaling by the rheumatoid arthritis shared epitope. Arthritis. Rheum. 2006; 54 (11): 3423–3432.Ling S., Lai A., Borschukova O. et al. Activation of nitric oxide signaling by the rheumatoid arthritis shared epitope. Arthritis. Rheum. 2006; 54 (11): 3423–3432.Holoshitz J., Ling S. et al. Nitric oxide signaling triggered by the rheumatoid arthritis shared epitope: a new paradigm for MHC disease association? Ann. N.Y. Acad. Sci. 2007; 1110: 73–83.Holoshitz J., Ling S. et al. Nitric oxide signaling triggered by the rheumatoid arthritis shared epitope: a new paradigm for MHC disease association? Ann. N.Y. Acad. Sci. 2007; 1110: 73–83.Bica B.E., Gomes N.M., Fernandes P.D. et al. Nitric oxide levels and the severity of juvenile idiopathic arthritis. Rheumatol. Int. 2007; 27 (9): 819–825.Bica B.E., Gomes N.M., Fernandes P.D. et al. Nitric oxide levels and the severity of juvenile idiopathic arthritis. Rheumatol. Int. 2007; 27 (9): 819–825.Braumvald E. Shattuck lecture cardiovascular medicine at the turn of millennium: triumph, concerns, and opportunities. N. Engl. J. Med. 1997; 337: 1360–1369.Braumvald E. Shattuck lecture cardiovascular medicine at the turn of millennium: triumph, concerns, and opportunities. N. Engl. J. Med. 1997; 337: 1360–1369.Насонов Е. Л. Атеротромбоз при ревматических заболеваниях: анализ патогенеза. Терапевтический архив. 1998; 9: 95–98.Насонов Е. Л. Атеротромбоз при ревматических заболеваниях: анализ патогенеза. Терапевтический архив. 1998; 9: 95–98.Shwager I., Jungi T.W. Effect of human recombinant cytokines of the induction of macrophage procoagulant activity. Blood. 1994; 83: 152–160.Shwager I., Jungi T.W. Effect of human recombinant cytokines of the induction of macrophage procoagulant activity. Blood. 1994; 83: 152–160.
The authors declare that there are no conflicts of interest present.